University of Queensland asked to develop vaccine for coronavirus

A Brisbane university has been asked to use rapid response technology to develop a vaccine for the coronavirus outbreak that has put eight Chinese cities in lockdown and the world on alert.

THE University of Queensland has been asked to develop a vaccine for the recent coronavirus outbreak at unprecedented speed, using new technology.

The Coalition for Epidemic Preparedness Innovations has requested the University use its recently developed rapid response technology to develop a vaccine as the

outbreak represented a significant challenge to the international community.

“There is a lot that is still unknown regarding how easily the virus is able to be transmitted between humans,” he said.

Passengers arrive at Sydney International Airport off a flight from the Chinese city of Wuhan, which is the epicentre of the coronavirus outbreak. Picture: Don Arnold/Getty Images

“Working with CEPI, The University of Queensland is using its vaccine technology to respond to this global health challenge.”

Head of the University’s School of Chemistry and Molecular Biosciences, Professor Paul Young said The University of Queensland had novel technology for the rapid generation of new vaccines from the knowledge of a virus’s genetic sequence information.

“The team hopes to develop a vaccine over the next six months, which may be used to help contain this outbreak,” he said.

“The vaccine would be distributed to first responders, helping to contain the virus from spreading around the world.”

Dr Keith Chappell, from UQ’s School of Chemistry and Molecular Biosciences and the Australian Institute for Bioengineering and Nanotechnology said the key to the speedy development was the “molecular clamp” technology, invented by UQ scientists and patented by UniQuest.

“The University of Queensland’s molecular clamp technology provides stability to the viral protein that is the primary target for our immune defence,” he said.

“The technology has been designed as a platform approach to generate vaccines against a range of human and animal viruses and has shown promising results in the laboratory targeting viruses such as influenza, Ebola, Nipah and MERS coronavirus.”